Insilico Medicine's AI-designed drug ISM6331 shows 40% ORR in mesothelioma trial
Insilico Medicine reported positive Phase 1 trial results for its generative AI-designed pan-TEAD inhibitor, ISM6331. The company announced that ISM6331 achieved a 40% Overall Response Rate (ORR) at a 130 mg dose in heavily pretreated mesothelioma patients. These findings were presented at ESMO 2026. The central claims regarding the drug's efficacy and AI design originate from Insilico Medicine, disseminated via press releases. Additionally, Insilico's leader has been sharing insights on AI-driven drug discovery, highlighting the company's advancements in the field.
3 articles from 3 outlets covered this story. The underlying claim is sourced from a press release.
What do all outlets agree on?
3 outlets covered “Insilico Medicine's AI-designed drug ISM6331 shows 40% ORR in mesothelioma trial”. All of them report the following:
- Insilico Medicine reported results for its pan-TEAD inhibitor ISM6331
- ISM6331 was designed using generative AI
- It achieved a 40% Overall Response Rate (ORR)
- The effective dose was 130 mg
- The trial involved heavily pretreated mesothelioma patients
- Results were presented at ESMO 2026
- Insilico Medicine's leader is discussing AI-driven drug discovery insights
Which outlets covered this?
All 3 articles found on this story, grouped by the stance of the piece. Every link goes to the original publisher.